TY - JOUR
T1 - Cryoballoon Ablation for the Treatment of Atrial Fibrillation in Patients With Concomitant Heart Failure and Either Reduced or Preserved Left Ventricular Ejection Fraction
T2 - Results From the Cryo AF Global Registry
AU - Rordorf, Roberto
AU - Scazzuso, Fernando
AU - Chun, Kyoung Ryul Julian
AU - Khelae, Surinder Kaur
AU - Kueffer, Fred J.
AU - Braegelmann, Kendra M.
AU - Okumura, Ken
AU - Al-Kandari, Fawzia
AU - On, Young Keun
AU - Földesi, Csaba
N1 - Publisher Copyright:
© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2021/12/21
Y1 - 2021/12/21
N2 - BACKGROUND: Heart failure (HF) and atrial fibrillation (AF) often coexist; yet, outcomes of ablation in patients with AF and concomitant HF are limited. This analysis assessed outcomes of cryoablation in patients with AF and HF. METHODS AND RESULTS: The Cryo AF Global Registr y is a prospective, multicenter registr y of patients with AF who were treated with cryoballoon ablation according to routine practice at 56 sites in 26 countries. Patients with baseline New York Heart Association class I to III (HF cohort) were compared with patients without HF. Freedom from atrial arrhyth-mia recurrence ≥30 seconds, safety, and health care utilization over 12-month follow-up were analyzed. A total of 1303 patients (318 HF) were included. Patients with HF commonly had preser ved lef t ventricular ejection fraction (81.6%), were more of ten women (45.6% versus 33.6%) with persistent AF (25.8% versus 14.3%), and had a larger lef t atrial diameter (4.4±0.9 versus 4.0±0.7 cm). Serious procedure-related complications occurred in 4.1% of patients with HF and 2.6% of patients without HF (P=0.188). Freedom from atrial arrhythmia recurrence was not dif ferent between cohorts with either paroxysmal AF (84.2% [95% CI, 78.6– 88.4] versus 86.8% [95% CI, 84.2– 89.0]) or persistent AF (69.6% [95% CI, 58.1– 78.5] versus 71.8% [95% CI, 63.2– 78.7]) (P=0.319). Af ter ablation, a reduction in AF-related symptoms and antiarrhythmic drug use was observed in both cohorts (HF and no-HF), and freedom from repeat ablation was not dif ferent between cohorts. Persistent AF and HF predicted a post-ablation cardiovascular rehospitalization (P=0.032 and P=0.001, respecti vel y). CONCLUSIONS: Cryoablation to treat patients with AF is similarly effective at 12 months in patients with and without HF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02752737.
AB - BACKGROUND: Heart failure (HF) and atrial fibrillation (AF) often coexist; yet, outcomes of ablation in patients with AF and concomitant HF are limited. This analysis assessed outcomes of cryoablation in patients with AF and HF. METHODS AND RESULTS: The Cryo AF Global Registr y is a prospective, multicenter registr y of patients with AF who were treated with cryoballoon ablation according to routine practice at 56 sites in 26 countries. Patients with baseline New York Heart Association class I to III (HF cohort) were compared with patients without HF. Freedom from atrial arrhyth-mia recurrence ≥30 seconds, safety, and health care utilization over 12-month follow-up were analyzed. A total of 1303 patients (318 HF) were included. Patients with HF commonly had preser ved lef t ventricular ejection fraction (81.6%), were more of ten women (45.6% versus 33.6%) with persistent AF (25.8% versus 14.3%), and had a larger lef t atrial diameter (4.4±0.9 versus 4.0±0.7 cm). Serious procedure-related complications occurred in 4.1% of patients with HF and 2.6% of patients without HF (P=0.188). Freedom from atrial arrhythmia recurrence was not dif ferent between cohorts with either paroxysmal AF (84.2% [95% CI, 78.6– 88.4] versus 86.8% [95% CI, 84.2– 89.0]) or persistent AF (69.6% [95% CI, 58.1– 78.5] versus 71.8% [95% CI, 63.2– 78.7]) (P=0.319). Af ter ablation, a reduction in AF-related symptoms and antiarrhythmic drug use was observed in both cohorts (HF and no-HF), and freedom from repeat ablation was not dif ferent between cohorts. Persistent AF and HF predicted a post-ablation cardiovascular rehospitalization (P=0.032 and P=0.001, respecti vel y). CONCLUSIONS: Cryoablation to treat patients with AF is similarly effective at 12 months in patients with and without HF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02752737.
KW - Atrial fibrillation
KW - Catheter ablation
KW - Heart failure
UR - https://www.scopus.com/pages/publications/85122903854
U2 - 10.1161/JAHA.121.021323
DO - 10.1161/JAHA.121.021323
M3 - Article
C2 - 34889108
AN - SCOPUS:85122903854
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 24
M1 - e021323
ER -